Skip to main
CAI

CAI (CAI) Stock Forecast & Price Target

CAI (CAI) Analyst Ratings

Based on 9 analyst ratings
Buy
Strong Buy 44%
Buy 33%
Hold 22%
Sell 0%
Strong Sell 0%

Bulls say

Caris Life Sciences is thriving as a precision medicine company due to their strong management team, successful cancer screening test results, and multiple partnerships with biopharma companies. They have seen a decline in shares, but are expected to continue growing through new tests and technology, despite facing competition and potential risks.

Bears say

Caris Life Sciences is a patient-centric, next-generation AI TechBio company that develops and commercializes solutions to transform healthcare through the use of comprehensive molecular information and artificial intelligence/machine learning algorithms at scale. While the company's data from its ACHIEVE 1 study is impressive, we believe it is challenging to compare its data set of ~3k samples to larger data sets of ~20-40k+ samples in the space. Additionally, we have concerns about the company's financial fitness and its ability to comply with legal requirements and receive adequate coverage and reimbursement from third-party payers.

CAI (CAI) has been analyzed by 9 analysts, with a consensus rating of Buy. 44% of analysts recommend a Strong Buy, 33% recommend Buy, 22% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of CAI and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About CAI (CAI) Forecast

Analysts have given CAI (CAI) a Buy based on their latest research and market trends.

According to 9 analysts, CAI (CAI) has a Buy consensus rating as of Jul 20, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $27.78, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $27.78, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

CAI (CAI)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.